Mercury Therapeutics

Mercury Therapeutics is a biopharmaceutical company dedicated to discovering and developing small molecule drugs that activate AMP-activated protein kinase (AMPK). Known as the "metabolic master switch," AMPK plays a vital role in regulating energy balance, making it a high-value target for metabolic disorders and oncology. The company's pipeline includes potent, selective activators designed to treat type 2 diabetes and obesity by improving insulin sensitivity and lipid metabolism. Furthermore, Mercury is investigating the anti-proliferative effects of AMPK activation in various cancers, including prostate and breast cancer. Their research is built upon the foundational work of world-renowned experts in AMPK biology and metabolic regulation.